Ownership and insider activity for Iovance Biotherapeutics, Inc. (IOVA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials.
Price
| Price | $9.87 |
| Market Cap | $4.4B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $166.5M | $145.4M | $82.2M | $14.0M | $67.3M | $78.2M | $231.7M | $114.9M | $115.7M | $163.1M |
| Short-term Investments | 0 | 0 | $386.4M | $293.1M | $562.1M | $426.2M | $240.1M | $165.0M | $208.1M | $133.9M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $151000 | $69.3M | $82.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $10.4M | $51.5M | $51.7M |
| Total Current Assets | $169.5M | $149.3M | $475.4M | $316.5M | $636.1M | $508.0M | $479.1M | $307.8M | $457.0M | $442.7M |
| Property, Plant & Equipment | $2.4M | $2.5M | $2.7M | $19.2M | $113.9M | $169.9M | $178.2M | $176.5M | $164.3M | $177.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $229.3M | $282.4M | $279.3M |
| Total Assets | $171.9M | $155.4M | $480.8M | $344.7M | $768.5M | $777.3M | $664.0M | $780.4M | $910.4M | $913.2M |
| Accounts Payable | $863000 | $1.2M | $2.7M | $15.6M | $13.5M | $27.4M | $26.6M | $33.1M | $27.5M | $22.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.0M |
| Total Current Liabilities | $5.0M | $9.9M | $14.4M | $39.1M | $54.9M | $89.2M | $91.5M | $110.3M | $122.3M | $138.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $1.0M | $1.0M | $1.0M | $1.0M | 0 |
| Total Liabilities | $5.0M | $9.9M | $14.6M | $45.7M | $112.0M | $155.7M | $164.3M | $195.7M | $200.0M | $214.6M |
| Retained Earnings | -$157.1M | -$249.2M | -$372.8M | -$570.6M | -$830.2M | -$1.17B | -$1.57B | -$2.01B | -$2.38B | -$2.78B |
| Total Equity | $166.9M | $145.5M | $466.2M | $299.0M | $656.5M | $621.7M | $499.6M | $584.6M | $710.4M | $698.6M |
| Total Debt | 0 | 0 | 0 | $11.5M | $51.7M | $71.5M | $85.4M | $75.9M | $58.3M | $48.4M |
| Net Debt | -$166.5M | -$145.4M | -$468.5M | -$295.6M | -$577.8M | -$432.9M | -$386.4M | -$204.0M | -$265.5M | -$248.5M |
| Working Capital | $164.5M | $139.4M | $461.0M | $277.4M | $581.2M | $418.8M | $387.6M | $197.5M | $334.7M | $304.3M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 4.35 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.30 |
Profitability
| Return on Equity | -40.51% |
| Return on Invested Capital | -36.60% |
| Return on Assets | -31.62% |
| Gross Margin | 116.30% |
| Operating Margin | -92.72% |
| Net Margin | -89.09% |
Related companies: ATXS · AVBP · CTMX · DNA · ERAS · MBX · MGTX
Explore sector: Healthcare · Biotechnology
More sections of IOVA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks